ІМУНОТЕРАПІЯ РАКУ ШЛУНКА. НОВІ ДАНІ
DOI:
https://doi.org/10.24061/1727-4338.XIV.4.54.2015.49Ключові слова:
рак, шлунок, імунотерапіяАнотація
Представлений огляд літератури 2012-2014рр. з імунотерапії раку шлунка. У поодиноких клінічних дослідженнях показано продовження виживання хворих при поширених раках шлунка на 2-4 місяці. Метод не вийшов з стадії клінічного експерименту.Посилання
Celluzzi CM, Mayordomo Jl, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. Journal of Experimental Medicine. 1996;183(l):83-287.
Gilboa E. DC-based cancer vaccines. Journal of Clinical Investigation. 2007;117(5):1195-1203.
Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with. Clinical Cancer Research. 2002;8(11):3394-3400.
Orange JS, Balias ZK. Clinical Immunology. Natural killer cells in human health and disease. 2006;118(1):1-10.
June CH. Principles of adoptive T cell cancer therapy. Journal of Clinical Investigation. 2007;117(5):1204-12.
Kim JH, Kang TH, Noh KH, et al. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunology Letters. 2010;134(1):47-54.
Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined withautologous cytokine-induced killer cells. Anticancer Research. 2006;26(3):2237-42.
Amedei A, Benagiano M, Bella C, et al. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol. 2011;12(4):4373- 78.
Kim YJ, Lim J, Kang JS, et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded TA cells. Cancer Letters. 2010;33(11):1789-95.
Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014;20(7):1657-66.
Turcotte S, Gros A, Tran E, et al. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. 2014;20(2):331-43.
Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies. Cancer Control. 2013;20(1);32-42.
Ina K, Kataoka T, Ando T. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem. 2013;13(5):681-88.
Zhao TT, Fan NN, Lin L, et al. Development of therapeutic antibodies for gastric and colorectal cancers. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012;41(3):345-52.
Tewari M, Sahai S, Mishra RR, et al. Dendritic cell therapy in advanced gastric cancer: a promising new hope. Surg Oncol. 2012;21(3):164-71.
Du XH, Xu YX, Chen L, et al. Treatment pattern of adoptive transfer of immune cells and its application in perioperative period for advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16(1):15-27.
Li Q, Chen J, Liu Y, et al. Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters. Oncol Rep. 2013;30(3):1215-22.
Tian WY, Chen WC, Li R, et al. Markers CD 40, VEGF, AKT, PI3K, and SI00 correlate with tumor stage in gastric cancer. Onkologie. 2013;36(1-2):26-31.
Song J, Ren H, Li Y, et al. rG17PE38, a novel immunotoxin target to gastric cancer with overexpressed CCK-2R. J Drug Target. 2013;21(4):375-82.
Wang L, Chang EW, Wong SC, et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2013;190(2):794-804.
Chen LJ, Zheng X, Shen YP, et al. Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother. 2013;62(3):553-61.
Fedele C, Carvalho S, Riccio G, et al. Effects of a human compact anti-ErbB2 antibody on gastric cancel. Gastric Cancer. 2014;17(1):107-15.
Tian Y, Jia X, Wang S, et al. SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predictimmunotherapy responsiveness. J Cancer Res Clin Oncol. 2014;140(7):1117-24.
Mao C, Mou X, Zhou Y, et al. Tumor-activated TCRyd(+) cells from gastric cancer patients induce the antitumor immune response of TCRyd T cells via their antigen-presenting cell-like eftects. J. Immunol Res. 2014;59(3):562.
Lin H, Wu X, Wang S, et al. In vitro repolarized tumor macrophages inhibit gastric tumor growth. Oncol Res. 2013;20(7):275-280.
Zhang L, Hou Y, Zhang J, et al. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett. 2013;5(6):1826-32.
Qu J, Hou Z, Han Q, et al. Intracellular poly initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions. J Interferon Cytokine Res. 2014;34(1):52-9.
Gang Y, Zhang X, He Y, et al. Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide. Biochem Cell Biol. 2012;90(6):701-08.
Du X, Jin R, Ning N, et al. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep. 2012;28(5):1743-49.
Liu H, Song J, Ya Z, et al. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med. 2013;6(4):953-56.
Wang ZM, Zhuang RY, Chen Y, et al. A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16(1):28-31.
Zhao H, Fan Y, Li H, et al. Immunotherapy with Cytokine-Induced Killer Cells as an Adjuvant Treatment for Advanced Gastric Carcinoma: A Retrospective Study of 165 Patients. Cancer Biother Radiopharm. 2013;18(4):145-68.
Ishigami S, Natsugoe S, Uenosono Y, et al. Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. Journal of Gastrointestinal Surger. 2003;7(6):735-39.
Cidon EU, Ellis SG, lnam Y, et al. Molecular targeted agents for gastric cancer: a step torwau towards personalized therapy. Cancers (Basel). 2013;5(1):64-91.
Ahn MS, Kang SY, Lee HW, et al. 5-Fluorouracil, mitomycin-c, and polysaccharide-k versi uracil-ftoratur and polysaccharide-K as adjuvant chemoimmunotherapy fc patients with locally advanced gastric cancer with curative resection. Onkologie. 2013;36(7-8):421-26.
Tanaka H, Muguruma K, Ohira M, et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer Res. 2012;32(8):3427-33.
Ishigami S, Natsugoe S, Tokuda K, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Letters. 2000;159(1):103-08.
Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61(12):2251-59.
Saito M, Yano K, Kamigaki T, et al. A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). Anticancer Res. 2013;33(7):2957-63.
Marano L, Porfidia R, Pezzella M, et al. Clinical and immunological impact of early postoperative enteral immunonutrition after total gastrectomy in gastric cancel patients, a prospective randomized study. Ann Surg Oncol. 2013;20(12):3912-18.
Fujitani K., Tsujinaka T, Fujita J, et al. Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer. Br J Surg. 2012;99(5):621-29.
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2017 R. W. Senjutovich, O. I. Ivaschuk, V. U. Bodiaka, T. V. Kruk, N. V. Zelinska, O. B. Chornyi, V. M. Pylypiv, M. A. Senjutovich
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Часопис користується «Типовим шаблоном положення про авторські права».
